Day One Biopharmaceuticals, INC. (DAWN) — SEC Filings

Q: What are the key financial highlights for Day One Biopharmaceuticals, INC.?

Key financial highlights for Day One Biopharmaceuticals, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Day One Biopharmaceuticals, INC.?

Key executives at Day One Biopharmaceuticals, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Day One Biopharmaceuticals, INC. stock?

Risk factors for Day One Biopharmaceuticals, INC. (DAWN) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Day One Biopharmaceuticals, INC.?

Forward-looking statements and predictions from Day One Biopharmaceuticals, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Day One Biopharmaceuticals, INC.. Recent 25-NSE filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider t

View Day One Biopharmaceuticals, INC. on SEC EDGAR

Overview

Day One Biopharmaceuticals, INC. (DAWN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 25-NSE filed on Apr 23, 2026: Nasdaq Stock Market LLC filed a Form 25-NSE on April 23, 2026, to report the removal from listing and registration of securities for Day One Biopharmaceuticals, Inc. This action is typically taken when securities have been matured, redeemed, or retired.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 42 neutral. The dominant filing sentiment for Day One Biopharmaceuticals, INC. is neutral.

Filing Type Overview

Day One Biopharmaceuticals, INC. (DAWN) has filed 1 25-NSE, 5 S, 2 POSASR, 18 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 2 10-K, 5 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

Day One Biopharmaceuticals Delisted from Nasdaq — 25-NSE · Apr 23, 2026 Risk: medium
Nasdaq Stock Market LLC filed a Form 25-NSE on April 23, 2026, to report the removal from listing and registration of securities for Day One Biopharmaceuticals,
S Filing — S · Apr 23, 2026
Day One Bio Files S-8 POS for Employee Stock Plan — S · Apr 23, 2026 Risk: low
Day One Biopharmaceuticals, Inc. filed an S-8 POS form on April 23, 2026, registering an unspecified number of securities to be offered under an employee benefi
S Filing — S · Apr 23, 2026
S Filing — S · Apr 23, 2026
Day One Bio Files S-8 POS for Employee Stock Plans — S · Apr 23, 2026 Risk: low
Day One Biopharmaceuticals, Inc. filed an S-8 POS form on April 23, 2026, registering an unspecified number of securities for issuance under its employee benefi
POSASR Filing — POSASR · Apr 23, 2026
POSASR Filing — POSASR · Apr 23, 2026
Day One Bio Files 8-K: Asset Disposition, Control Changes — 8-K · Apr 23, 2026 Risk: medium
Day One Biopharmaceuticals, Inc. filed an 8-K on April 23, 2026, reporting several material events. These include the termination of a material definitive agree
Day One Biopharma Files 8-K — 8-K · Nov 24, 2025 Risk: low
On November 24, 2025, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial
Day One Biopharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 13, 2025 Risk: medium
On November 12, 2025, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal ex
DAWN's Q3 Loss Widens Amidst Plummeting License Revenue — 10-Q · Nov 4, 2025 Risk: high
Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $19.7 million for the three months ended September 30, 2025, a significant decline from the net i
Day One Biopharma Reports Director Changes and Executive Compensation Updates — 8-K · Oct 10, 2025 Risk: medium
On October 7, 2025, Day One Biopharmaceuticals, Inc. reported changes in its board of directors and executive compensation arrangements. Specifically, the compa
Day One Biopharma Posts No Revenue, $109.8M Net Loss in Q2 — 10-Q · Aug 5, 2025 Risk: high
Day One Biopharmaceuticals, Inc. reported no product revenue for the three and six months ended June 30, 2025, consistent with the prior year, indicating its pr
Day One Biopharma Files 8-K on Shareholder Vote Matters — 8-K · Jun 3, 2025 Risk: low
On June 2, 2025, Day One Biopharmaceuticals, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, made on
Day One Bio Q1 2025 Update: R&D, Revenue Details — 10-Q · May 6, 2025 Risk: medium
Day One Biopharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including research and developme
Day One Biopharma Files Definitive Proxy Statement — DEF 14A · Apr 11, 2025 Risk: low
Day One Biopharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on April 11, 2025, for its annual meeting of stockholders on June 2, 2025. The fil
Day One Bio files 10-K/A amendment — 10-K/A · Mar 6, 2025 Risk: low
Day One Biopharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The filing, submitted on March 6
10-K Filing — 10-K · Feb 25, 2025
Day One Biopharma Files 8-K — 8-K · Jan 13, 2025 Risk: low
On January 13, 2025, Day One Biopharmaceuticals, Inc. filed a Form 8-K to report its current status. The filing confirms the company's principal executive offic
Day One Biopharma Elects New Directors, Adjusts Officer Compensation — 8-K · Nov 20, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. announced on November 20, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the co
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
Day One Bio Q3 2024 Filing — 10-Q · Oct 30, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. filed its Q3 2024 10-Q report on October 30, 2024. The company's fiscal year ends on December 31st. Key financial data points a
AI Day1 LLC Ups Stake in Day One Biopharma to 14.9% — SC 13D/A · Aug 5, 2024 Risk: medium
On August 5, 2024, AI Day1 LLC filed an amendment (Amendment No. 4) to its Schedule 13D concerning Day One Biopharmaceuticals, Inc. The filing indicates a chang
Day One Bio Files Q2 2024 10-Q — 10-Q · Aug 2, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key finan
Day One Biopharma Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 30, 2024 Risk: medium
On July 30, 2024, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
Day One Biopharma Files 8-K on Financials — 8-K · Jul 30, 2024 Risk: low
On July 30, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report detailing the results of operations and financial condition. The filing also included Reg
Day One Biopharma Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 25, 2024 Risk: medium
On July 23, 2024, Day One Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
Day One Biopharmaceuticals Files 8-K — 8-K · Jun 18, 2024 Risk: low
On June 17, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and registered sec
Day One Biopharma Files 8-K — 8-K · Jun 12, 2024 Risk: low
On June 12, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2000 Sierr
Shionogi Acquires Day One Biopharmaceuticals — 8-K · May 30, 2024 Risk: low
On May 29, 2024, Day One Biopharmaceuticals, Inc. announced the completion of its acquisition by Shionogi & Co., Ltd. The transaction was completed following th
Day One Biopharm Files 8-K on Shareholder Vote — 8-K · May 24, 2024 Risk: low
Day One Biopharmaceuticals, Inc. filed an 8-K on May 24, 2024, reporting on a matter submitted to a vote of its security holders on May 23, 2024. The filing doe
Day One Biopharmaceuticals Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 6, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. (DAWN) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Day One Biopharmaceuticals, Inc. filed a 10-Q report for th
8-K Filing — 8-K · Apr 24, 2024
Day One Biopharma Files Proxy Statement for May Meeting — DEF 14A · Apr 5, 2024 Risk: low
Day One Biopharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on April 5, 2024, for its annual meeting on May 23, 2024. The company, incorporate
Day One Biopharmaceuticals Files 8-K Report — 8-K · Mar 7, 2024 Risk: low
On March 4, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No
Day One Biopharmaceuticals Files 2023 Annual Report (10-K) — 10-K · Feb 26, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. (DAWN) filed a Annual Report (10-K) with the SEC on February 26, 2024. Filed its 2023 10-K report on February 26, 2024. The com
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
Atlas Venture Amends Day One Bio Stake, Updates Ownership Data — SC 13G/A · Feb 9, 2024 Risk: low
Atlas Venture Fund XI, L.P. and its affiliated entities filed an amended Schedule 13G/A on February 9, 2024, indicating their ownership in Day One Biopharmaceut
FMR LLC & Abigail Johnson Trim Day One Bio Stake to 4.558% — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Day One Biopharmaceuticals, Inc. (NASDAQ: DAW
BlackRock Discloses Significant Stake in Day One Biopharmaceuticals — SC 13G · Jan 29, 2024
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in Day One Biopharmaceuticals, Inc. as of December 31,
Day One Bio Files 8-K on Officer Changes, Reg FD Disclosure — 8-K · Jan 17, 2024
Day One Biopharmaceuticals, Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing indicates changes related t
Day One Bio Files 8-K, Confirms Nasdaq Listing Under DAWN — 8-K · Jan 8, 2024
Day One Biopharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly trade

Risk Profile

Risk Assessment: Of DAWN's 31 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Day One Biopharmaceuticals, INC.'s most recent 10-Q filing (Nov 4, 2025):

Revenue: $39.8M
Net Income: -$19.7M
EPS: N/A
Debt-to-Equity: 0.14
Cash Position: $43.3M
Operating Margin: -60.9%
Total Assets: $513.8M
Total Debt: $62.9M

Key Executives

Dr. David J. Bearss
Ms. Jennifer L. Sim
Dr. Robert J. Smith
Len Blavatnik
Alejandro Moreno
Abigail P. Johnson

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on a few key products for revenue, making pipeline diversification and successful commercialization critical. The market is competitive, with companies vying for market share and seeking strategic partnerships or acquisitions.

Top Tags

sec-filing (6) · biotech (4) · corporate-governance (4) · 10-Q (4) · financials (4) · amendment (4) · institutional-ownership (3) · securities-registration (2) · 8-k (2) · filing (2)

Key Numbers

Net Loss (Q3 2025): $19.7M — Increased from $37.0M net income in Q3 2024
Net Loss (9 Months 2025): $86.0M — Widened from $29.8M net loss in 9 months 2024
Product Revenue (9 Months 2025): $102.6M — Increased significantly from $28.3M in 9 months 2024
License Revenue (Q3 2025): $1.3M — Decreased sharply from $73.7M in Q3 2024
Cash and Cash Equivalents (Sep 30, 2025): $43.3M — Decreased from $125.0M at Dec 31, 2024
Net Cash Used in Operating Activities (9 Months 2025): $89.6M — Increased from $48.1M in 9 months 2024
Concentration of Product Revenue (Q3 2025): 98.6% — Two individual customers accounted for this percentage of total net product revenue
Research and Development Expenses (9 Months 2025): $107.2M — Decreased from $165.9M in 9 months 2024
Product Revenue: $0 — for the six months ended June 30, 2025, indicating pre-commercial stage
Research and Development Expenses: $75.3M — for the six months ended June 30, 2025, a decrease from $80.1M in 2024
Selling, General and Administrative Expenses: $38.5M — for the six months ended June 30, 2025, an increase from $32.2M in 2024
Net Loss: $109.8M — for the six months ended June 30, 2025, consistent with $109.9M in 2024
Conformed Period of Report: 2025-06-30 — the end date of the reporting period for this 10-Q
Reporting Period End Date: 2025-03-31 — Covers the first quarter of 2025
Prior Year Start Date: 2024-01-01 — For comparative financial data

Forward-Looking Statements

{"claim":"FMR LLC will continue to monitor its position in Day One Biopharmaceuticals, potentially making further minor adjustments based on market conditions or company performance.","entity":"FMR LLC","targetDate":"Within the next 6-12 months","confidence":"medium"}

Related Companies

DAYO

Frequently Asked Questions

What are the latest SEC filings for Day One Biopharmaceuticals, INC. (DAWN)?

Day One Biopharmaceuticals, INC. has 45 recent SEC filings from Jan 2024 to Apr 2026, including 18 8-K, 6 10-Q, 5 S. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of DAWN filings?

Across 45 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 42 neutral. The dominant sentiment is neutral.

Where can I find Day One Biopharmaceuticals, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Day One Biopharmaceuticals, INC. (DAWN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Day One Biopharmaceuticals, INC.?

Key financial highlights from Day One Biopharmaceuticals, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for DAWN?

The investment thesis for DAWN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Day One Biopharmaceuticals, INC.?

Key executives identified across Day One Biopharmaceuticals, INC.'s filings include Dr. David J. Bearss, Ms. Jennifer L. Sim, Dr. Robert J. Smith, Len Blavatnik, Alejandro Moreno and 1 others.

What are the main risk factors for Day One Biopharmaceuticals, INC. stock?

Of DAWN's 31 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Day One Biopharmaceuticals, INC.?

Recent forward-looking statements from Day One Biopharmaceuticals, INC. include guidance on {"claim":"FMR LLC will continue to monitor its position in Day One Biopharmaceuticals, potentially making further minor .